Objective To retrospectively analyse the clinical efficacy of patients with multidrug-resistant tuberculosis on bedaquiline and clofazimine-containing treatment regimens.Methods A total of 60 cases of mul-tidrug-resistant tuberculosis patients in the Sixth People's Hospital of Wenzhou City were collected from September 2020 to July 2022.They were divided into an observation group and a control group,with 30 patiets in each group.The patients in control group were treated with linezolid,levofloxacin(or moxifloxacin),cycloserine,pyrazi-namide,and propionate isoniazide,while the patients in observation group were treated with betaquiline,clofaz-imine instead of pyrazinamide and propionate isoniazide.The other drugs used by the two groups were the same,and the treatment duration for both groups was 24 weeks,with the total treatment corse not yet completed.The ef-fectiveness was evaluated based on the sputum culture conversion rate and lung lesion absorption rate after 24 weeks of treatment.The safety was assessed by analyzing changes in electrocardiogram QTc,liver function abnor-malities,and gastrointestinal reactions.Results The sputum bacterial conversion rates in the observation group were 79％(22/28)and 21％(6/28)at 8 and 12 weeks of treatment,respectively,which were higher than the control group's 62％(18/29)and 17％(5/29)(P＜0.05).The short-term effectiveness rate of the observation group was 93％(26/28),which was higher than the control group's 76％(22/29)(P＜0.05).In terms of safety,two patients in the observation group withdrew from the treatment group due to significant prolongation of QTc interval;one patient in the control group withdrew due to hepatic failure.There was no statistically significant difference in adverse reac-tions between the two groups(P＞0.05).Conclusion The short-term clinical efficacy and tolerability of the be-daquiline and clofazimine-containing regimen for the treatment of multidrug-resistant tuberculosis are better.
关键词
抗药性,多药/贝达喹啉/氯法齐明/药物评价/抗结核药物
Key words
Drug resistance,multiple/Bedaquiline/Clofazimine/Drug evaluation/Anti-tuberculosis drugs
维普
万方数据